According to an SEC filing, Fremont, CA-based ARYx plans to sell 5 million shares of its stock at an estimated offering price of $14 to $16 each, which would raise about $67.8 million if the company hit the middle of that range. Report

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.